The Human Variable 

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

Traditional medicine isolates diagnoses by organ or specialty. CYNAERA’s terrain logic views the body as an interdependent system where immune, endocrine, and autonomic signals co-determine stability. The Playbook applies three key insights from the Primary Chronic Trigger (PCT) Blueprint. Chronic illness begins with temporal ignition, an event that tips an unstable terrain. Chronicity persists when recovery conditions (RC) remain incomplete.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”

This future ready framework was built from real world data, patient-led insights and cutting-edge biomarker science. 35–50 million Americans. 25–30% global prevalence. $1 trillion annual impact. The world can’t afford diagnostics that guess, it needs diagnostics that know. Read the groundbreaking Composite Diagnostic Fingerprint for Long COVID, authored by patient-turned-subject matter expert Cynthia Adinig. Nobel Prize worthy thinking. Welcome to CYNAERA. Where technology m